Healthcare / Pharmaceutical / MedTechTechnical Analysis Guide

JNJ Stock Analysis

Johnson & Johnson

💡 Quick Answer

Across 4 APEX technical signals, JNJ is currently split between bullish and bearish readings — 0 bullish, 0 bearish as of 2026-07-08. Run a live analysis to see the current composite score.

JNJ is the anchor holding in virtually every large institutional healthcare portfolio. Its Dividend King status and AAA credit rating (one of only two U.S.

RSI Behavior: Ultra-stable 42-65 rangePharmaceutical Pipeline: Oncology growth driverTalc Litigation: Ongoing legal overhang

Johnson & Johnson is a diversified healthcare company with two primary segments: Innovative Medicine (pharmaceuticals including immunology blockbusters Stelara and Tremfya, plus oncology) and MedTech (surgical robotics, orthopedics, cardiovascular). JNJ completed the spinoff of its consumer products division (Kenvue) in 2023, transforming itself into a pure-play healthcare company with higher growth and margins. JNJ has raised its dividend for 61 consecutive years. One of the longest streaks in any industry.

LIVE CHART·JNJ. DailyPowered by TradingView

Open JNJ on TradingView ↗Affiliate link

Get live JNJ signal analysis

APEX runs 8 signals on JNJ in real time: RSI, MACD, Fibonacci, Volume, and more.

Analyze JNJ Now →

Why Do Traders Watch JNJ?

JNJ is the anchor holding in virtually every large institutional healthcare portfolio. Its Dividend King status and AAA credit rating (one of only two U.S. companies with this rating) make it a "must own" for income and quality investors. ATR of 1-1.5% is among the lowest of any S&P 500 stock. JNJ functions as a sector sentiment indicator: when JNJ is weak, the whole healthcare sector is under pressure.

Is JNJ a Buy Right Now? Current Signal Readings

📊RSI BehaviorUltra-stable 42-65 range

JNJ's extreme earnings stability produces the most predictable RSI behavior of any healthcare stock. RSI below 45 on JNJ is a reliable buy signal. Income and quality investors immediately accumulate at those levels. The stock rarely stays below RSI 45 for more than 2-3 weeks before recovering.

💊Pharmaceutical PipelineOncology growth driver

JNJ's oncology segment. Featuring multiple myeloma drug Darzalex and prostate cancer drug Erleada. Is its fastest-growing pharmaceutical franchise. Phase 3 data readouts from oncology pipeline compounds have produced 3-5% moves. Monitor ASCO and ASH conference abstracts for pipeline catalysts 6-8 weeks before major oncology conferences.

📊Talc LitigationOngoing legal overhang

JNJ's talc-related lawsuits (from its former consumer business, retained post-Kenvue spinoff) create persistent legal overhang. Adverse court rulings or failed bankruptcy settlement attempts have produced 3-7% single-day selloffs. Monitor Texas Two-Step bankruptcy proceeding updates as binary risk events.

📊Dividend Growth61+ consecutive years

JNJ's 61-year dividend growth streak creates automatic institutional demand at any point the dividend yield rises meaningfully above 3%. Income-focused funds and ETFs that track dividend aristocrats generate systematic buying pressure that limits downside at these yield levels.

📋 JNJ Key Stats for Traders

⚡ATR (14-day)1-1.5% of price

📦Avg daily volume~7-12 million shares

🎯Key metricDarzalex growth + MedTech revenue

📋Dividend streak61+ consecutive years

🔗 Related Stocks

UNH ABBV PFE MDT

Run a live JNJ analysis

APEX combines RSI, MACD, Fibonacci, Volume, and 4 more signals into one composite score in under 30 seconds.

Analyze JNJ Free →

Advanced charting for JNJ on TradingView ↗

💬 Frequently Asked Questions. JNJ

QIs JNJ a good stock to buy right now?

AWhether JNJ is a buy depends on its current technical positioning. JNJ is the anchor holding in virtually every large institutional healthcare portfolio. Its Dividend King status and AAA credit rating (one of only two U.S. companies with this rating) make it a "must own" for income and quality investors. ATR of 1-1.5% is among the lowest of any S&P 500 stock. JNJ functions as a sector sentiment indicator: when JNJ is weak, the whole healthcare sector is under pressure. Run a live APEX analysis at apexstockintel.com to see the current composite score, RSI, and MACD signals. Updated every trading day.

QWhat are the most important technical signals for JNJ?

AThe four key signals for JNJ are: RSI Behavior (Ultra-stable 42-65 range). JNJ's extreme earnings stability produces the most predictable RSI behavior of any healthcare stock. RSI below 45 on JNJ is a reliable buy signal. Income and quality investors immediately accumulate at those levels. The stock rarely stays below RSI 45 for more than 2-3 weeks before recovering.. Pharmaceutical Pipeline (Oncology growth driver). JNJ's oncology segment. Featuring multiple myeloma drug Darzalex and prostate cancer drug Erleada. Is its fastest-growing pharmaceutical franchise. Phase 3 data readouts from oncology pipeline compounds have produced 3-5% moves. Monitor ASCO and ASH conference abstracts for pipeline catalysts 6-8 weeks before major oncology conferences.. Talc Litigation (Ongoing legal overhang). JNJ's talc-related lawsuits (from its former consumer business, retained post-Kenvue spinoff) create persistent legal overhang. Adverse court rulings or failed bankruptcy settlement attempts have produced 3-7% single-day selloffs. Monitor Texas Two-Step bankruptcy proceeding updates as binary risk events.. Dividend Growth (61+ consecutive years). JNJ's 61-year dividend growth streak creates automatic institutional demand at any point the dividend yield rises meaningfully above 3%. Income-focused funds and ETFs that track dividend aristocrats generate systematic buying pressure that limits downside at these yield levels.

QWhat is JNJ's RSI telling traders right now?

AJNJ's extreme earnings stability produces the most predictable RSI behavior of any healthcare stock. RSI below 45 on JNJ is a reliable buy signal. Income and quality investors immediately accumulate at those levels. The stock rarely stays below RSI 45 for more than 2-3 weeks before recovering. APEX scores JNJ's RSI as part of its 8-factor composite signal. Updated daily.

QHow does JNJ behave technically compared to other Healthcare / Pharmaceutical / MedTech stocks?

AJNJ is in the Healthcare / Pharmaceutical / MedTech sector. Johnson & Johnson is a diversified healthcare company with two primary segments: Innovative Medicine (pharmaceuticals including immunology blockbusters Stelara and Tremfya, plus oncology) and MedTech (surgical robotics, orthopedics, cardiovascular). JNJ completed the spinoff of its consumer products division (Kenvue) in 2023, transforming itself into a pure-play healthcare company with higher growth and margins. JNJ has raised its dividend for 61 consecutive years. One of the longest streaks in any industry. Key stats: ATR (14-day): 1-1.5% of price, Avg daily volume: ~7-12 million shares, Key metric: Darzalex growth + MedTech revenue, Dividend streak: 61+ consecutive years.

QWhat MACD signals work best for JNJ?

AMACD measures momentum direction via the relationship between two exponential moving averages. Bullish crossovers (MACD line crossing above the signal line) indicate increasing upward momentum, while bearish crossovers signal the opposite. APEX tracks JNJ's MACD histogram direction daily.

OTHER STOCK GUIDES

Technology49

+−